Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel

…, CA Benson, A Carr, JS Currier, MP Dubé… - JAIDS Journal of …, 2002 - journals.lww.com
Objective: Alterations in glucose and lipid metabolism, lactic acidemia, bone disorders, and
abnormal body fat distribution have been recognized recently as frequent complications …

Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy …

MP Dubé, JH Stein, JA Aberg… - Clinical Infectious …, 2003 - academic.oup.com
Dyslipidemia is a common problem affecting HIV-infected patients receiving antiretroviral
therapy. Since publication of preliminary guidelines in 2000 [1], numerous studies have …

The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response

…, CA Kemper, GN Beall, D Johnson, MP Dubé… - Aids, 1999 - journals.lww.com
The value of patient-reported adherence to antiretroviral th... : AIDS The value of patient-reported
adherence to antiretroviral therapy in predicting virologic and immunologic response : …

[HTML][HTML] Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection

…, SW Snyder, C Pettinelli, MP Dubé… - … England Journal of …, 2003 - Mass Medical Soc
Background The optimal sequencing of antiretroviral regimens for the treatment of infection
with human immunodeficiency virus type 1 (HIV-1) is unknown. We compared several …

[HTML][HTML] Prophylaxis against Disseminated Mycobacterium avium Complex with Weekly Azithromycin, Daily Rifabutin, or Both

DV Havlir, MP Dubé, FR Sattler… - … England Journal of …, 1996 - Mass Medical Soc
Background Azithromycin is active in treating Mycobacterium avium complex disease, but it
has not been evaluated as primary prophylaxis in patients with human immunodeficiency …

Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS …

…, RA Parker, BR Cotter, JS Currier, MP Dubé… - Journal of the American …, 2008 - jacc.org
Objectives : This study evaluated the effects of 3 class-sparing antiretroviral therapy (ART)
regimens on endothelial function in human immunodeficiency virus (HIV)-infected subjects …

State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary

…, DP Kotler, JS Currier, JD Lundgren, MP Dubé… - Circulation, 2008 - Am Heart Assoc
… therapy (HAART; chaired by Drs Judy Currier and Jens Lundgren); (3) the effects of HIV
infection and antiretroviral therapy on the heart and vasculature (chaired by Drs Michael Dubé

Protease inhibitor-associated hyperglycaemia

MP Dubé, DL Johnson, JS Currier, JM Leedom - The Lancet, 1997 - thelancet.com
Inherited mutations in the BRCA1 gene confer a predisposition to breast and ovarian cancer.
1 We report the results of BRCA1-mutation screening in a family at high risk of breast and …

Disorders of glucose metabolism in patients infected with human immunodeficiency virus

MP Dubé - Clinical infectious diseases, 2000 - academic.oup.com
New-onset diabetes mellitus, clinically similar to type 2 diabetes, will affect a small proportion
(1%–6%) of patients infected with human immunodeficiency virus (HIV) who are treated …

Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides

MP Dube, RA Parker, P Tebas, SK Grinspoon… - Aids, 2005 - journals.lww.com
… The authors acknowledge the invaluable assistance of Gina-Bob Dubé and Kathy L. Flynn
with managing the references, Lawrence A. Hirsch of Quest Diagnostics for coordinating …